Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Pharmacodynamic Effects of MEDI0382 in Obese Subjects With Non-Alcoholic Fatty Liver Disease (NAFLD)/ Non-Alcoholic Steatohepatitis (NASH)

NCT04019561 is registered in ClinicalTrials.gov with MedImmune LLC as lead sponsor.

NCT NCT04019561
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04019561 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Pharmacodynamic Effects of MEDI0382 in Obese Subjects With Non-Alcoholic Fatty Liver Disease (NAFLD)/ Non-Alcoholic Steatohepatitis (NASH)
Lead sponsor
MedImmune LLC
Phase
Phase 2
Overall status
Completed
Start date
September 23, 2019
Completion date
May 6, 2021
Enrollment
74 (actual)
Sites
27

Conditions

As the registry lists them; a condition with its own page is linked.

non-alcoholic fatty liver disease (nafld), non-alcoholic steatohepatitis (nash)